Silo Pharma Inc.

05/29/2026

Silo Pharma continues expanding its CNS pipeline strategy through the exploration of innovative psychedelic-assisted therapeutic approaches.

The company’s latest initiative reinforces its focus on combining novel compounds, differentiated delivery systems, and measurable clinical endpoints to address underserved neurological and psychiatric conditions.

Read more: https://bit.ly/4nfwBRu

05/27/2026

Silo Pharma’s latest initiative reflects growing interest in therapies designed to address the underlying structural and neuropsychiatric impacts of traumatic brain injury.

Current treatment options remain limited to symptom management, highlighting the need for innovative CNS therapeutic approaches capable of improving long-term functional outcomes.

In case you missed it: https://bit.ly/4nfwBRu

04/29/2026

Silo Pharma (Nasdaq: SILO) commends a wave of coordinated U.S. federal actions that are rapidly advancing the development of psychedelic-based therapeutics for mental health and substance use disorders. Building on last weekend’s executive initiative to fast-track these treatments, multiple agencies have taken meaningful steps this week to accelerate research, clinical progress, and regulatory clarity across the sector.

These actions point to a broader shift across funding, clinical advancement, and regulatory prioritization in the development of new treatments for PTSD and related disorders.

Read more: https://ir.silopharma.com/single-news-releases/?webmasterId=104586&qmodStoryID=5172080466485565

05/28/2025

Silo Pharma & Resyca Partner for a drug-device study of the formulation-specific microchip-based nasal spray system used in its lead asset SPC-15, an intranasal prophylactic treatment for PTSD.

Read more:

Silo Pharma (Nasdaq: SILO) partnered with Resyca BV to conduct a drug-device study for their lead asset, SPC-15, an...

05/22/2025

Did you know there has not been a new drug approval for PTSD in nearly 25 years, affecting an estimated 3.9% of the world’s population? Silo is addressing this unmet need with SPC-15, a prophylactic treatment for PTSD.

Learn about SPC-15’s potential: https://bit.ly/3RMCdVh

05/21/2025

Silo Pharma (Nasdaq: SILO) Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15. Read the press release here: https://bit.ly/3FnTII8

05/20/2025

Silo’s clear timeline to first-in-human clinical trials for lead asset SPC-15, an intranasal prophylactic treatment for PTSD, is pending FDA guidance on pre-IND.

Stay updated on the latest SPC-15 development news: https://bit.ly/48iQ5M9

05/15/2025

Silo Pharma reaches clear regulatory path to clinical trials for intranasal PTSD therapy, SPC-15

We've initiated the FDA-requested 7-day safety and toxicology study at Frontage Laboratories, supplementing our ongoing GLP-compliant toxicokinetic studies of SPC-15.

Positive preclinical data from these studies, if achieved, would support an IND submission for SPC-15 in 2025. Should Silo receive approval of the IND, Silo would proceed to a first-in-human Phase 1 clinical trial for SPC-15.

Read our full announcement: https://bit.ly/457iMxx

05/15/2025

Silo has a disruptive market potential in the central nervous system therapeutics industry with a projected CAGR of 10.5% for CNS drugs during the period 2025 (~$155.5 B) to 2034 (~$381.3 B).

Learn more: https://bit.ly/3YCAEws

05/14/2025

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15. Read the press release here: https://bit.ly/3YK4Ndh